✦HEALTH · 30% off Purgo Labs✦
Topical Research Hub

TB-500
Research Hub

A reference for TB-500 (thymosin beta-4 fragment) research: mechanism, what the animal and human evidence actually covers, safety findings, legal status, and how to verify a vial. Research use only; we do not publish dosing protocols.

Peptide Class
Thymosin Beta-4 Fragment
Sold as "TB-500"
Either the Ac-LKKTETQ fragment (7 aa, ~889 Da) or full-length thymosin beta-4 (43 aa, 4,963 Da)
How to tell
The certificate's measured mass identifies which one is in the vial
Primary Mechanism
G-actin binding; cell migration and angiogenesis in preclinical models
FDA Status
Not approved — research use only
Human evidence
Full-length thymosin beta-4 has reached human trials (eye-drop formulation); the TB-500 fragment has not
Established dose
None. No approved product and no human dosing data for the fragment

Frequently Asked Questions

Common questions about TB-500 from researchers

What is TB-500?

TB-500 is a synthetic peptide derived from Thymosin Beta-4, a naturally occurring protein found in virtually all human and animal cells. It is primarily studied for its role in tissue repair, wound healing, and angiogenesis. TB-500 acts by sequestering G-actin, which promotes cell migration and the formation of new blood vessels.

What is TB-500 used for in research?

In animal and cell models, TB-500 and thymosin beta-4 are studied for tendon and ligament repair, cardiac tissue after injury, wound healing, neuroregeneration and inflammation. Human data exist only for full-length thymosin beta-4, developed by RegeneRx Biopharmaceuticals; its most advanced program is an eye-drop formulation, and an injectable cardiac program has not produced published efficacy results. None of this establishes an effect for the TB-500 fragment in people.

What is the difference between TB-500 and BPC-157?

TB-500 and BPC-157 are both studied for tissue repair but work through distinct mechanisms. TB-500 primarily acts through actin sequestration and angiogenesis, while BPC-157 works through VEGF upregulation and nitric oxide pathways. They are often stacked together because their mechanisms are complementary rather than redundant.

Is there an established TB-500 dose?

No. TB-500 is not an approved drug, the fragment has never been tested in a human clinical trial, and the amounts used in published animal studies were chosen for those models and routes; they do not translate into a human figure. The 'loading and maintenance' schedules that circulate online come from forums, not trials. Compound Review does not publish dosing protocols. TB-500 is sold for laboratory research only and is not for human or animal consumption; the research profile lists the published studies with citations for anyone reviewing the literature.

Is TB-500 the same as Thymosin Beta-4?

Strictly, TB-500 is a synthetic fragment of thymosin beta-4: the actin-binding region (residues 17–23, Ac-LKKTETQ) of the 43-residue protein. In practice vendors use the name for both the fragment and the full-length protein, which differ about fivefold in mass. Whether the fragment reproduces the full protein's studied effects has not been established. The measured mass on a certificate is the quickest way to see which one a vial contains.

Source TB-500 from Purgo Labs

≥99% purity · Third-party COA on every batch · Ships same day